Recent scientific exploration into psychedelics provides evidence that these powerful substances can profoundly reshape human brain function and mental health. A wave of new research suggests that lysergic acid diethylamide, widely known as LSD, alters electrical brain rhythms to promote mental flexibility, elevate mood, and even protect against neurological damage. These discoveries point to an expanding medical frontier where altered states of consciousness might translate into targeted treatments for conditions ranging from depression to alcohol addiction.
Psychiatric and neurological disorders affect hundreds of millions of people globally, often causing immense personal and societal disruption. Conditions like major depressive disorder, alcohol use disorder, and severe epilepsy frequently resist conventional treatments. This leaves many patients with limited medical options and a poor quality of life. This unmet medical need has prompted a renewed focus on classic psychedelics as potential therapeutic agents.
Drugs like LSD produce intense shifts in perception, mood, and cognitive processing. They achieve this primarily by binding to serotonin receptors in the brain. Receptors are specialized protein structures on the surface of brain cells that receive chemical signals to trigger biological responses. When a psychedelic chemical locks into these receptors, it initiates a cascade of neurochemical events that changes how different brain regions communicate with one another.
Scientists explore these mechanisms to understand exactly how psychedelics disrupt rigid mental habits. The entropic brain hypothesis serves as a guiding concept in much of this work. In physics, entropy refers to a state of randomness and disorder. In neuroscience, higher entropy means the brain enters a less predictable, more dynamic state of operation. By increasing brain entropy, psychedelics might dissolve entrenched neural patterns, offering temporary flexibility that helps patients build healthier mental habits.
To understand how LSD alters consciousness, a research team examined its effects on tiny, localized clusters of brain cells. Paolo La-Torraca-Vittori, a researcher at the University of Pavia, and Livio Tarchi of the University of Florence led the project, which was published in the European Journal of Neuroscience. The authors wanted to map how the drug influences spontaneous brain waves and local electrical synchronization in resting adults.
The team analyzed an open-access database containing brain scans of 15 healthy adults. Each participant received an intravenous placebo on one day and a moderate dose of LSD on another day. The researchers measured the amplitude of low-frequency fluctuations, a metric that tracks the power of slow brain waves in a specific area. They also measured regional homogeneity, which assesses how well neighboring brain cells synchronize their electrical firing.
Under the influence of the drug, both metrics dropped significantly across the cortex. This suggests that local brain activity became faster, noisier, and less synchronized. The researchers noted that these drops were especially pronounced in areas that process vision and incoming physical touch. This localized fragmentation forces the brain to abandon its normal hierarchical structure, where sensory data is processed in specialized silos before moving up to associative regions.
Instead of operating in isolated clusters, the drug flattens the neural hierarchy, allowing the brain to broadly integrate visual and physical sensations. The study also highlighted disruptions in the default mode network, a brain system tied to daydreaming and self-reflection. Disruptions in this network tend to correlate with the loss of a defined conscious self, a common psychological experience reported by people using psychedelics.
The authors mapped these physical brain changes against the known locations of various chemical receptors. They found that the desynchronization patterns strongly mirrored the distribution of dopamine receptors and alternative serotonin receptors, expanding the assumed primary targets of the drug. Brain areas with fewer of these specific receptors experienced the greatest decreases in local synchronization, indicating a complex biological interaction.
Another recent project built on similar brain scanning data to explore how LSD bridges the gap between basic perception and abstract thought. Lingyu Zhang, a researcher at the Beijing University of Posts and Telecommunications, led the analysis. The research, published in PLOS Computational Biology, paired brain scans with advanced computer modeling to estimate internal chemical shifts.
Healthy brain function operates on a delicate balance between excitatory neurons and inhibitory neurons. Excitatory neurons act like biological accelerators that encourage brain cells to fire, while inhibitory neurons act like brakes to keep the system organized. Zhang and the research team built a dynamic computer simulation to estimate how this chemical balance changes across the cerebral cortex, the brain’s wrinkled outer layer.
The computer model estimated a sharp drop in the excitatory-to-inhibitory ratio within sensory and motor processing regions. This means the biological brakes became much stronger in areas dealing with basic sensory input. On the flip side, the activation ratio increased in abstract associative regions, essentially taking off the brakes and making those neurons highly active.
By suppressing sensory anchors and boosting abstract thought, the drug blurs the boundaries that usually separate physical perception from internal cognition. The research team also looked for patterns of global synchronization, measuring when rhythmic waves of activity aligned across different brain networks. They found that the drug enhanced global synchrony, pulling the brain out of its segregated, independent routines and into a unified firing state.
This physiological shift provides evidence for how the substance fosters cognitive flexibility. The authors suggest that this neural remodeling aligns closely with subjective reports of intense introspection and an altered perception of the physical world. The drug binds to specific serotonin receptors, which then manipulate the primary excitatory neurotransmitters in the sensory cortex, sending a ripple effect across the entire mind.
Scientists are also exploring whether tiny, sub-hallucinogenic amounts of psychedelics can produce beneficial neurological changes. James Glazer, a researcher in the Department of Psychiatry at Northwestern University, led a project testing how low doses alter the way the brain processes emotional rewards. The findings were published in the Journal of Psychopharmacology.
People experiencing depression often show a blunted capacity to process rewards, meaning their brains do not react strongly to winning or receiving positive feedback. This stunted emotional processing can drain motivation and make it difficult to learn from mistakes. The research team set out to determine if a low dose of the drug could normalize this altered reward processing in individuals with mild depression.
The experiment involved 34 healthy volunteers who reported varying levels of depressed mood on standard psychological questionnaires. Each person attended two sessions, receiving either a 26-microgram dose of LSD or an inactive placebo. This low dose was specifically chosen to alter basic brain function without inducing intense visual hallucinations that could interfere with taking a test.
During the sessions, the volunteers played a computerized game that offered small monetary rewards for quick reactions. As they played, researchers tracked their real-time brain waves using electroencephalography, a technique that records electrical signals from sensors placed over the scalp. They focused on a prolonged electrical wave that reflects the deep emotional value of an outcome, which typically corresponds with activation in the amygdala.
The amygdala is a tiny structure deep in the brain that regulates emotional processing. In healthy brains, losing a game triggers a massive electrical spike in this region that dwarfs the reaction to winning, driving the person to adapt and focus harder. During the placebo session, participants with higher depression levels showed a stunted electrical response to losing the game, fitting the classic profile of depressive blunting.
When given the active drug, this biological dynamic shifted significantly. The substance widened the gap between losing and winning scenarios for these individuals, generating a much larger emotional response to negative feedback. This suggests the drug temporarily restored a more typical, robust neural reaction to missed rewards.
This electrical shift directly mirrored the subjective experiences of the participants. Volunteers who showed the strongest neural increase also reported the highest improvements in positive mood during the active session. This elevated emotional state lingered, with those participants reporting lower overall depressed mood two days after the laboratory visit.
Building on the concept of low doses, a separate team tested a frequent microdosing schedule for individuals with major depressive disorder. Dimitri Daldegan-Bueno, a pharmacy researcher at the University of Auckland, led the pilot project published in Progress in Neuropsychopharmacology & Biological Psychiatry. The scientists wanted to see if acute mood improvements occurred in a clinical population practicing remote self-administration.
The trial enrolled 19 adults diagnosed with major depression. They began with a monitored laboratory session where they received an eight-microgram dose of liquid LSD held under the tongue, a process known as sublingual administration. Blood samples were taken to track pharmacokinetics, which is the study of how the body absorbs, distributes, and eliminates a drug from the bloodstream.
Following the initial lab visit, participants took the drug home and consumed it twice a week for eight weeks. They used a customized smartphone application to track their sleep, daily functionality, and specific mood metrics. They were allowed to slightly adjust their at-home dose between four and twenty micrograms to find their ideal personal balance.
The blood analysis revealed a distinct physiological pattern regarding drug metabolism. Individuals who naturally processed the drug faster, resulting in lower blood concentrations, tended to slowly increase their home doses. This suggests that participants were successfully adjusting their drug intake to achieve a consistent subjective effect, compensating for their unique internal biology.
The daily tracking data showed specific patterns of acute mood elevation. On the exact days they consumed the microdose, participants logged higher levels of energy, creativity, and social connection. They also reported feeling happier and less irritable on the two days immediately following the dose. Experiencing surges in creative energy might encourage depressed individuals to engage in rewarding social behaviors, creating a positive feedback loop over time.
The participants did not report the drug feeling weaker or stronger over the eight weeks. This lack of tolerance or sensitization is a notable finding, as many psychiatric drugs quickly lose their effectiveness without dosage increases. A formal clinical interview conducted at the end of the entire trial showed an average drop in depression severity of sixty percent across the group.
The influence of psychedelics extends beyond controlled laboratory settings, affecting broad population health trends. James M. Zech, a researcher at Florida State University, analyzed federal health data to explore the link between recreational psychedelic use and alcohol addiction. The study was published in the Journal of Psychoactive Drugs.
Alcohol use disorder is a pervasive public health challenge marked by an inability to control drinking despite the resulting physical and social harm. Seeking alternative treatments, researchers have recently focused on substances like psilocybin and MDMA. Zech and his colleagues wanted to see if the therapeutic signals found in clinical trials also appeared among recreational users in the general public.
The team pooled survey data from nearly 140,000 American adults collected between 2021 and 2023. They adjusted their statistical models to account for factors like age, income, education level, and the use of other substances like tobacco and cannabis. The researchers then looked for connections between past-year drug use and a formal diagnosis of alcohol use disorder.
The analysis revealed that adults who used LSD in the past year were significantly less likely to meet the criteria for alcohol use disorder. The adjusted data indicated a 30 percent reduction in likelihood compared to non-users. Among individuals who did have the disorder, recent users reported approximately 15 percent fewer symptoms overall.
Other popular substances, such as ketamine and MDMA, did not show a similar statistical association with alcohol problems over the same twelve-month period. The authors suggest that the psychological shifts often reported by LSD users, such as increased openness and decreased neuroticism, might reduce the underlying mental drivers of heavy drinking.
In a surprising departure from psychiatric research, scientists have also identified potential neuroprotective benefits of psychedelics. A team at the University of Toronto tested LSD in a mouse model of severe seizures. The research produced two related papers published in Next Research and Brain Research.
The project began strictly as a safety test. Some patients experience both epileptic seizures and functional seizures, which are psychological events that mimic epilepsy without the abnormal electrical discharges. Before proposing psychedelics as a psychological treatment for functional seizures, the researchers needed to verify the drug would not worsen actual epilepsy.
“This work started in a completely different direction than it ended up going in,” study author Brenden Rabinovitch told PsyPost. The researchers administered either a saline solution or an active dose of the drug to adolescent mice. They then injected the animals with kainic acid, a chemical that overstimulates neurons and reliably induces severe seizures.
The behavioral outcomes were highly unexpected. In the control group, nearly 40 percent of the male mice entered a life-threatening state of continuous seizures, known as status epilepticus, and many died. In stark contrast, male mice treated with the higher dose of LSD showed a complete absence of this dangerous state, and none died. The drug appeared to halt the progression of the most severe convulsions.
The behavioral responses among the mice were completely unanticipated. “When we saw that certain behavioural characteristics of seizures actually improved in these mice, we were shocked to say the least,” Rabinovitch previously told PsyPost.
To uncover the hidden biological mechanism, the team implanted electrodes into the brains of freely moving mice. They found that the drug caused a broad reduction in the power and amplitude of electrical brain waves. The recorded brain signals became less predictable and more chaotic, heavily aligning with the entropic brain theory.
Because epileptic seizures rely on hypersynchronized, rigid patterns of electrical firing, this drug-induced chaos may act as a neuroprotective barrier. By lowering the power of neural rhythms, the substance makes it difficult for hypersynchronized seizure activity to organize and spread across the brain. The drug essentially introduces enough noise into the system to prevent the seizure from generalizing.
Despite the therapeutic potential of classic psychedelics, their hallucinogenic effects pose significant risks for individuals with a family history of psychosis or schizophrenia. To solve this problem, scientists at the University of California, Davis engineered a new chemical analogue named JRT. The research was published in the Proceedings of the National Academy of Sciences.
Psychedelics are highly effective at promoting neuroplasticity, which is the brain’s ability to grow new connections and repair damaged circuits. This growth is essential for treating conditions characterized by the shrinking or atrophy of neurons. The research team aimed to modify the structure of LSD just enough to preserve this brain-repairing capacity while stripping away the hallucinogenic experience.
“One of the hallmarks of schizophrenia is atrophy of neurons in the cortex,” lead author David E. Olson told PsyPost in a 2025 interview. “We decided to engineer an analogue of LSD with lower hallucinogenic potential in the hopes that this neuroplasticity-promoting compound might be useful for treating these patients.”
The scientists achieved this goal by flipping the position of exactly two atoms in the drug’s complex molecular structure. This tiny adjustment removed a specific chemical bond that typically interacts with the serotonin 2A receptor to produce hallucinations. The new compound, named after the graduate student who designed it, had to be synthesized entirely from scratch in the laboratory.
Laboratory tests using rat brain cells showed that JRT promoted substantial growth in dendritic branches, exceeding even the performance of the original drug. In live mice, a single dose increased synapse density in the prefrontal cortex and reversed brain damage induced by chronic stress. This provides evidence that the new analogue maintains the profound neuroplasticity benefits of its parent compound.
Importantly, JRT did not trigger head-twitch behaviors in mice, a standard biological marker used by scientists to predict hallucinogenic activity. It also produced antidepressant-like outcomes and improved cognitive flexibility in stressed animals. The drug showed high selectivity for serotonin receptors, completely avoiding other receptor types that often cause weight gain and sedation in standard psychiatric medications.
“I was surprised that transposing only two atoms was sufficient to drastically change the pharmacology of LSD,” Olson previously told PsyPost. “Even small chemical alterations to the structures of psychedelics have the potential to profoundly improve their safety and efficacy profiles.”
Evaluating these scientific advancements requires close attention to study design and inherent limitations. Several of the brain imaging experiments and microdosing trials relied on very small groups of participants. Expanding these participant pools in future studies is necessary to ensure the observed physiological changes reliably apply to the broader adult population. The demographics in many of these trials were also highly restricted, and future projects must include more diverse groups to validate the findings.
Participant expectations exert a massive influence on psychiatric research, especially in open-label trials where volunteers know they are receiving a famous psychedelic compound. This awareness can easily trigger a placebo effect, where patients report better moods simply because they anticipate a positive outcome. Proving true clinical efficacy requires randomized, double-blind trials that compare active drug groups against inactive placebo groups to isolate actual chemical benefits.
Translating animal research into human treatments presents another layer of scientific complexity. The seizure protection and non-hallucinogenic brain repair experiments were conducted in rodents, and human brain physiology is vastly more intricate. Subjective human experiences often differ from behavioral markers seen in mice, meaning extensive clinical trials will be needed to verify safety and effectiveness in clinical environments.
Looking forward, medical researchers plan to track patients over much longer periods to determine if repeated dosing builds tolerance or sustains long-term healing. Scientists are also focused on exploring how new chemical analogues might rescue damaged brain tissue in debilitating neurodegenerative conditions. As researchers map the precise timing of neural changes, they hope to develop targeted interventions that harness the brain-altering power of psychedelics safely and predictably.
The study, “Knocking at the Doors of Perception: Relating LSD Effects on Low-Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI,” was authored by Paolo La-Torraca-Vittori, Livio Tarchi, Elisa Arrigo, Stefano Lanterna, Eleonora Tosi, Arne Doose, Fulvia Palesi, Doris Pischedda, Valdo Ricca, Paolo Fusar-Poli, and Stefano Damiani.
The study, “Lysergic acid diethylamide-derived excitatory/inhibitory ratio change enhances global synchrony in functional brain dynamics,” was authored by Lingyu Zhang, Weiyang Shi, Ziyang Zhao, Zhichao Wang, Congying Chu, Bokai Zhao, Jiaqi Zhang, Qianhui Liu, Yueheng Lan, and Tianzi Jiang.
The study, “LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial,” was authored by Dimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, Anna Forsyth, Soo Hee Jeong, William Evans, Malak Alshakhouri, Robin J. Murphy, Lisa Reynolds, Nicholas Hoeh, Nathan Allen, Frederick Sundram, David B. Menkes, and Suresh Muthukumaraswamy.
The study, “Reward-related neural activity after low doses of LSD in participants with depressed mood,” was authored by James Glazer, Hanna Molla, Royce Lee, Robin Nusslock, and Harriet de Wit.
The study, “Lysergic acid diethylamide inhibits status epilepticus and mortality in a mouse model of acute kainic acid-induced motor seizures,” was authored by BS Rabinovitch, W Hu, C Tang, N Silverman, EC Lewis, and PL Carlen.
The study, “Lysergic acid diethylamide modulates hippocampal and cortical local field potential oscillatory rhythms in male mice,” was authored by B.S. Rabinovitch, N. Silverman, D. Ji, D. Shizgal, E.C. Lewis, and P.L. Carlen.
The study, “The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample,” was authored by James M. Zech, Jérémie Richard, and Grant M. Jones.
The study, “Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential,” was authored by Jeremy R. Tuck, Lee E. Dunlap, Yara A. Khatib, Cassandra J. Hatzipantelis, Sammy Weiser Novak, Rachel M. Rahn, Alexis R. Davis, Adam Mosswood, Anna M. M. Vernier, Ethan M. Fenton, Isak K. Aarrestad, Robert J. Tombari, Samuel J. Carter, Zachary Deane, Yuning Wang, Arlo Sheridan, Monica A. Gonzalez, Arabo A. Avanes, Noel A. Powell, Milan Chytil, Sharon Engel, James C. Fettinger, Amaya R. Jenkins, William A. Carlezon Jr., Alex S. Nord, Brian D. Kangas, Kurt Rasmussen, Conor Liston, Uri Manor, and David E. Olson.
Leave a comment
You must be logged in to post a comment.